A Multicenter, Randomized, Double-blind, Placebo-controlled, Proof-of-Concept Study of Ustekinumab in Subjects With Active Systemic Lupus Erythematosus

Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled, Proof-of-Concept Study of Ustekinumab in Subjects With Active Systemic Lupus Erythematosus

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Jun 2018

At a glance

  • Drugs Ustekinumab (Primary) ; Ustekinumab (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 16 Jun 2018 Results presented at the 19th Annual Congress of the European League Against Rheumatism
    • 16 Jun 2018 Results (n=102) presented at the 19th Annual Congress of the European League Against Rheumatism.
    • 15 May 2018 Planned End Date changed from 21 Mar 2019 to 21 Mar 2023.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top